Drug Patents owned by Eli Lilly And Co

1. Drug name - AXIRON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784878 ELI LILLY AND CO Transdermal delivery rate control using amorphous pharmaceutical compositions Jul, 2023

(9 months from now)

US8993520 ELI LILLY AND CO Method and composition for transdermal drug delivery Jun, 2026

(3 years from now)

US9180194 ELI LILLY AND CO Method and composition for transdermal drug delivery Jun, 2026

(3 years from now)

US8419307 ELI LILLY AND CO Spreading implement Feb, 2027

(4 years from now)

US8807861 ELI LILLY AND CO Spreading implement Feb, 2027

(4 years from now)

US9289586 ELI LILLY AND CO Spreading implement Feb, 2027

(4 years from now)

US8435944 ELI LILLY AND CO Method and composition for transdermal drug delivery Sep, 2027

(5 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Treatment: A method of transdermally delivering testosterone; A method of increasing the testosterone blood level of an adult male subject in need thereof; A method of increasing the testosterone blood level of a person in need thereof; A method of transdermal administration of a physiologically active agent to a subject.

Dosage: SOLUTION, METERED;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
30MG/1.5ML ACTUATION SOLUTION, METERED;TRANSDERMAL Discontinued

2. Drug name - BAQSIMI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10213487 ELI LILLY AND CO Nasal powder formulation for treatment of hypoglycemia Feb, 2036

(13 years from now)

US10894133 ELI LILLY AND CO Device for dispensing a fluid product Jan, 2038

(15 years from now)

US10765602 ELI LILLY AND CO Medication delivery systems and methods Sep, 2039

(17 years from now)

Drugs and Companies using GLUCAGON ingredient

Treatment: Treatment of severe hypoglycemia in patients with diabetes

Dosage: POWDER;NASAL

More Information on Dosage
Strength Dosage Availability
3MG POWDER;NASAL Prescription

3. Drug name - OLUMIANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8158616 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
Jun, 2030

(7 years from now)

CN103788098A ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitor
May, 2016

(6 years ago)

CN102026999A ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitors
Mar, 2029

(6 years from now)

CN102026999B ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitor
Mar, 2029

(6 years from now)

IN270765B ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitors
Mar, 2029

(6 years from now)

IN201001863P3 ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitors
Mar, 2029

(6 years from now)

EP2288610A1 ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitors
Mar, 2029

(6 years from now)

EP2288610B8 ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitors
Mar, 2029

(6 years from now)

EP2288610B1 ELI LILLY AND CO Azetidine And Cyclobutane Derivatives As Jak Inhibitors
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420629 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors Mar, 2029

(6 years from now)

Drugs and Companies using BARICITINIB ingredient

Treatment: Treatment of rheumatoid arthritis

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription

4. Drug name - REYVOW

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7423050 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Apr, 2025

(2 years from now)

US11053214 ELI LILLY AND CO Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Dec, 2037

(15 years from now)

CN100352817C ELI LILLY AND CO As
Mar, 2023

(5 months from now)

CN1642939A ELI LILLY AND CO As
Mar, 2023

(5 months from now)

IN238831B ELI LILLY AND CO A Substituted Pyridinoylipieridines Compound As 5-Ht If Agonists
Mar, 2023

(5 months from now)

IN200401392P2 ELI LILLY AND CO Pyridinoylpiperidines As 5-Ht1F Agonists
Mar, 2023

(5 months from now)

EP1492786B1 ELI LILLY AND CO Pyridinoylpiperidines As 5-Ht1F Agonists
Mar, 2023

(5 months from now)

EP1492786A1 ELI LILLY AND CO Pyridinoylpiperidines As 5-Ht1F Agonists
Mar, 2023

(5 months from now)

EP3551617A1 ELI LILLY AND CO Compositions And Methods Related To Pyridinoylpiperidine 5-Ht1F Agonists
Dec, 2037

(15 years from now)

EP3551617B1 ELI LILLY AND CO Compositions And Methods Related To Pyridinoylpiperidine 5-Ht1F Agonists
Dec, 2037

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748459 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists Mar, 2023

(5 months from now)

Drugs and Companies using LASMIDITAN SUCCINATE ingredient

Treatment: Acute treatment of migraine

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription
EQ 200MG BASE TABLET;ORAL Discontinued

5. Drug name - VERZENIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7855211 ELI LILLY AND CO Protein kinase inhibitors
Dec, 2029

(7 years from now)

CN102264725A ELI LILLY AND CO Protein Kinase Inhibitor
Dec, 2029

(7 years from now)

CN102264725B ELI LILLY AND CO Protein Kinase Inhibitors
Dec, 2029

(7 years from now)

IN297760B ELI LILLY AND CO Protein Kinase Inhibitors
Dec, 2029

(7 years from now)

IN201103454P4 ELI LILLY AND CO Protein Kinase Inhibitors
Dec, 2029

(7 years from now)

EP2379528B1 ELI LILLY AND CO Protein Kinase Inhibitors
Dec, 2029

(7 years from now)

EP2379528A1 ELI LILLY AND CO Protein Kinase Inhibitors
Dec, 2029

(7 years from now)

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription
150MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.